Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.

@article{Kalantzi2018ComparisonOT,
  title={Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.},
  author={K. Kalantzi and I. Ntalas and V. Chantzichristos and M. Tsoumani and Dimitrios Adamopoulos and C. Asimakopoulos and A. Bourdakis and Petros Darmanis and A. Dimitriadou and Stefanos Gkiokas and Konstantinos Ipeirotis and Kyriaki Kitikidou and I. Klonaris and A. Kostaki and D. Logothetis and Konstantinos Mainas and Theodoros Mais and A. Maragiannis and K. Martiadou and Konstantinos Mavronasos and Ioannis Michelongonas and D. Mitropoulos and G. Papadimitriou and A. Papadopoulos and Miltiadis Papaioakeim and Kosmas Sofillas and Sotiria Stabola and E. Stefanakis and Dimitrios P. Stergiou and M. Thoma and Alexandros Zenetos and S. Zisekas and J. Goudevenos and D. Panagiotakos and A. Tselepis},
  journal={Current vascular pharmacology},
  year={2018}
}
BACKGROUND Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events. OBJECTIVE We performed a randomised, multicentre, phase 4 clinical trial to compare the clinical efficacy and safety of triflusal versus aspirin, administered for 12 months in patients eligible to receive a cyclooxygenase-1 (COX-1) inhibitor. METHOD Patients with stable coronary artery… Expand

References

SHOWING 1-10 OF 24 REFERENCES
Triflusal for preventing serious vascular events in people at high risk.
  • 58
Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study
  • 4
  • PDF
...
1
2
3
...